Abstract
The aim of this work is to develop and validate a microbiological assay for ceftriaxone with a view to the employment of this method to assess photo-stability in commercial products. The experimental conditions included: (1) ceftriaxone standard solution in concentrations of 2.6 μg/mL, 3.2 μg/mL, 4.0 μg/mL, 5.0 μg/mL and 6.3 μg/mL, using phosphate buffer pH 6.0 as diluent, (2) Petri dishes prepared by adding 21-mL of antibiotic medium as base layer and 4-mL of the same medium, inoculated with Bacillus subtilis (ATCC 6633) in a proportion of 0.5% and (3) incubation at 37ºC for 18 hours. The method showed specificity, good linearity in the range from 2.6 to 6.3 μg/mL, as well as good precision (RSD repeatability of 1.7% and RSD intermediate precision of 2.2%) and accuracy (recovery of 101.1%). Commercial samples of ceftriaxone were exposed to light in their primary and secondary packing, being afterwards directly exposed to light. The potencies of commercial samples were then determined by the developed and validated microbiological assay. The results indicate that primary and secondary packing provide satisfactory protection of ceftriaxone from light.
Keywords: Agar diffusion, Antibiotic assay, Ceftriaxone, Cephalosporin, Dosage form, Method development, Method validation, Microbial assay, Photo-stability, Stability study
Current Pharmaceutical Analysis
Title:Development and Validation of Microbiological Assay for Ceftriaxone and its Application in Photo-stability Study
Volume: 9 Issue: 1
Author(s): Felipe Rebello Lourenco, Marcus Augusto Lyrio Traple, Rogerio Takao Okamoto and Terezinha de Jesus Andreoli Pinto
Affiliation:
Keywords: Agar diffusion, Antibiotic assay, Ceftriaxone, Cephalosporin, Dosage form, Method development, Method validation, Microbial assay, Photo-stability, Stability study
Abstract: The aim of this work is to develop and validate a microbiological assay for ceftriaxone with a view to the employment of this method to assess photo-stability in commercial products. The experimental conditions included: (1) ceftriaxone standard solution in concentrations of 2.6 μg/mL, 3.2 μg/mL, 4.0 μg/mL, 5.0 μg/mL and 6.3 μg/mL, using phosphate buffer pH 6.0 as diluent, (2) Petri dishes prepared by adding 21-mL of antibiotic medium as base layer and 4-mL of the same medium, inoculated with Bacillus subtilis (ATCC 6633) in a proportion of 0.5% and (3) incubation at 37ºC for 18 hours. The method showed specificity, good linearity in the range from 2.6 to 6.3 μg/mL, as well as good precision (RSD repeatability of 1.7% and RSD intermediate precision of 2.2%) and accuracy (recovery of 101.1%). Commercial samples of ceftriaxone were exposed to light in their primary and secondary packing, being afterwards directly exposed to light. The potencies of commercial samples were then determined by the developed and validated microbiological assay. The results indicate that primary and secondary packing provide satisfactory protection of ceftriaxone from light.
Export Options
About this article
Cite this article as:
Rebello Lourenco Felipe, Augusto Lyrio Traple Marcus, Takao Okamoto Rogerio and de Jesus Andreoli Pinto Terezinha, Development and Validation of Microbiological Assay for Ceftriaxone and its Application in Photo-stability Study, Current Pharmaceutical Analysis 2013; 9 (1) . https://dx.doi.org/10.2174/1573412911309010011
DOI https://dx.doi.org/10.2174/1573412911309010011 |
Print ISSN 1573-4129 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-676X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Identification of Antifungal Agents Using Combinatorial Approach: An Overview$
Current Medicinal Chemistry - Anti-Infective Agents Mass Spectrometry in the Study of Hemoglobin: from Covalent Structure to Higher Order Assembly
Current Organic Chemistry Intravenous Immunoglobulin (IVIG) in Rheumatologic Diseases: A Review of its Mechanism of Action
Current Rheumatology Reviews Antiviral Agents in the Prevention and Treatment of Virus-Induced Diabetes
Anti-Infective Agents in Medicinal Chemistry subject Index To Volume 2
Current Medicinal Chemistry - Central Nervous System Agents Development of Reverse Phase Ultra-fast Liquid Chromatography Using Ion-pairing Reagent for Quantitative Assessment of Ceftriaxone in Rat Serum and Cerebrospinal Fluid
Current Pharmaceutical Analysis Small Neuroscience: The Nanostructure of the Central Nervous System and Emerging Nanotechnology Applications
Current Nanoscience Mast Cells: Target and Source of Neuropeptides
Current Pharmaceutical Design Editorial: [Hot Topic: Central Nervous System Drugs in the Treatment of Neurological Disorders]
Central Nervous System Agents in Medicinal Chemistry The Changing Face of HIV/AIDS in Treated Patients
Current HIV Research Hypersensitivity Reactions to Quinolones
Current Pharmaceutical Design Preface
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Evaluation of Small Molecule Tuberculostats for Targeting Tuberculosis Infections of the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Plasminogen Activator System and Vascular Disease
Current Vascular Pharmacology Transforming Growth Factor-β Signaling in Motor Neuron Diseases
Current Molecular Medicine Invasive Aspergillosis: Focus on New Approaches and New Therapeutic Agents
Current Medicinal Chemistry - Anti-Infective Agents A New Frontier in the Treatment of Cancer: NK-1 Receptor Antagonists
Current Medicinal Chemistry A PPARdelta Agonist Reduces Amyloid Burden and Brain Inflammation in a Transgenic Mouse Model of Alzheimers Disease
Current Alzheimer Research Antisense Oligonucleotides as an Innovative Therapeutic Strategy in the Treatment of High-Grade Gliomas
Recent Patents on CNS Drug Discovery (Discontinued) Novel Targets for the Development of Anti-Herpes Compounds
Infectious Disorders - Drug Targets